Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Non-Current Assets (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Non-Current Assets for 2 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 10.91% to $9.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $39.9 million through Dec 2025, down 16.01% year-over-year, with the annual reading at $9.7 million for FY2025, 10.91% down from the prior year.
  • Non-Current Assets hit $9.7 million in Q4 2025 for Xilio Therapeutics, up from $9.6 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $13.4 million in Q1 2024 to a low of $9.6 million in Q3 2025.